Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel
Open accessAbstract
Bispecific antibodies (BsAbs) are emerging as an important novel class of immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be more widely used in clinical practice. However, this new class of therapies is associated with a distinct adverse event (AE) profile that includes cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, as well as AEs leading to increased infection risk such as cytopenias and hypogammaglobulinemia, and infections themselves. As preliminary data with this class of agents shows an increased risk of infections as compared with conventional MM treatment regimens, such as immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies (mAbs), guidance on infection monitoring, prophylaxis and treatment is required. This review provides consensus recommendations from a panel of 13 global experts, following a meeting in August 2022. The meeting objective was to review existing literature and identify relevant information on infections with all BsAbs in patients with MM, as well as to discuss clinical experience of experts in managing these infections. The recommendations outlined here can be used to guide management of infection risk factors, such as hypogammaglobulinemia and neutropenia. In addition, they can be used to guide the monitoring, prophylaxis, and treatment of bacterial, viral and fungal infections, including emerging infections of interest, such as coronavirus 2019 (COVID-19), and the use of vaccinations prior to and during BsAb treatment. The recommendations have been graded by the panel based on level of data available. Key recommendations include universal herpes simplex and varicella zoster virus prophylaxis, screening for hepatitis B virus reactivation risk in all patients, monthly intravenous immunoglobulin treatment for immunoparesis and in the absence of life-threatening infectious manifestations, use of colony-stimulating factors in patients with Grade 3 neutropenia, universal pneumocystis jirovecii pneumonia prophylaxis and no routine anti-fungal prophylaxis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Early infection prevention, including immunoglobulin replacement per IMWG guidelines, reduces high-grade infections in patients receiving bispecific antibodies.
“Results further emphasize the importance of early infection prevention in patients receiving bispecific antibodies, including use of immunoglobulin replacement per IMWG guidelines to reduce high-grade infections.36–40”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [36]
The Consensus recommendations (Risk factors for infection; page not provided) recommend monthly IVIG for patients with immunoparesis receiving bispecific antibodies, and discuss immunoglobulin replacement for patients at particular infection risk. The passages do not identify these as IMWG guidelines or report that early replacement reduces high-grade infections; the claim states that outcome more firmly than this source supports. (LLM, conf=0.85)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Pappas, P. G., Kauffman, C. A., Andes, D. R., Clancy, C. J., Marr, K. A., Ostrosky-Zeichner, L., Reboli, A. C., Schuster, M. G., Vazquez, J. A., Walsh, T. J., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ933 · Cited by 4,200 · see citing works
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806 · see citing works
Teclistamab in Relapsed or Refractory Multiple Myeloma
Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203478 · Cited by 1,269 · cited 12× · see citing works
“1% patients) received treatment with G-CSF [24].”
BackgroundResultInfluentialSelf-citationLetermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation
Marty, F. M., Ljungman, P. T., Chemaly, R. F., Maertens, J. A., Dadwal, S., Duarte, R. F., Haider, S., Ullmann, A. J., Katayama, Y., Brown, J. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706640 · Cited by 1,243 · see citing works
Self-citationTalquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744 · see citing works
Self-citationOutcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy.
Gandhi, U. H., Cornell, R. F., Lakshman, A., Gahvari, Z. J., McGehee, E., Jagosky, M. H., Gupta, R., Varnado, W., Fiala, M. A., Chhabra, S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0435-7 · Cited by 616 · see citing works
Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
Blimark, C. H., Holmberg, E. C., Mellqvist, U., Landgren, O., Björkholm, M., Hultcrantz, M. L., Kjellander, C., Turesson, I., & Kristinsson, S. Y. (2014) · Haematologica · doi:10.3324/haematol.2014.107714 · Cited by 525 · see citing works
Usmani, S. Z., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., Miguel, J. F. S., Oriol, A., Rosiñol, L., Chari, A., Bhutani, M., Karlin, L., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01338-6 · Cited by 335 · see citing works
Self-citationAnti–B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma
Topp, M. S., Duell, J., Zugmaier, G., Attal, M., Moreau, P., Langer, C., Krönke, J., Facon, T., Salnikov, A. V., Lesley, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02657 · Cited by 304 · see citing works
Self-citationCAR T cell therapies for patients with multiple myeloma
Mikkilineni, L., & Kochenderfer, J. N. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0427-6 · Cited by 270 · see citing works
Mateos, M.-V., Weisel, K., De Stefano, V., Goldschmidt, H., Delforge, M., Mohty, M., Cavo, M., Vij, R., Lindsey-Hill, J., Dytfeld, D., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01531-2 · Cited by 252 · see citing works
Self-citationRaje, N. S., Anaissie, E., Kumar, S. K., Lonial, S., Martin, T., Gertz, M. A., Krishnan, A., Hari, P., Ludwig, H., O'Donnell, E., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00283-0 · Cited by 212 · see citing works
Self-citationOekelen, O. V., Gleason, C., Agte, S., Srivastava, K., Beach, K. F., Aleman, A., Kappes, K., Banu, R., Bermúdez-González, M. C., Chernet, R. L., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.06.014 · Cited by 208 · see citing works
Chari, A., Samur, M., Martínez‐López, J., Cook, G., Biran, N., Yong, K., Hungria, V., Engelhardt, M. M., Gay, F., Feria, A. G., et al. (2020) · Blood · doi:10.1182/blood.2020008150 · Cited by 190 · see citing works
Self-citationDrayson, M. T., Bowcock, S. J., Planche, T., Iqbal, G., Pratt, G., Yong, K., Wood, J., Raynes, K., Higgins, H. B., Dawkins, B., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30506-6 · Cited by 169 · see citing works
Costa, L. J., Wong, S. W. K., Bermúdez, A., de la Rubia, J., Mateos, M., Ocio, E. M., Rodríguez‐Otero, P., Miguel, J. F. S., Li, S., Sarmiento, R., et al. (2019) · Blood · doi:10.1182/blood-2019-122895 · Cited by 156 · see citing works
Self-citationMolecular imaging of bacterial infections: Overcoming the barriers to clinical translation
Ordoñez, A. A., Sellmyer, M. A., Gowrishankar, G., Ruiz-Bedoya, C. A., Tucker, E. W., Palestro, C. J., Hammoud, D. A., & Jain, S. K. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax8251 · Cited by 152 · see citing works
Arcos, I. L., Iacoboni, G., Aguilar‐Guisado, M., Alsina, L., de Heredia, C. D., Guasch, C. F., García‐Cadenas, I., García‐Vidal, C., González‐Vicent, M., Hernani, R., et al. (2020) · Infection · doi:10.1007/s15010-020-01521-5 · Cited by 145 · see citing works
Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Boccadoro, M., Moreau, P., Miguel, J. F. S., Cavo, M., Pawlyn, C., Zweegman, S., Facon, T. T. F., Driessen, C., Hájek, R., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01016-0 · Cited by 142 · see citing works
Self-citationKhanam, A., Chua, J. V., & Kottilil, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115497 · Cited by 138 · see citing works
D’Souza, A., Shah, N. D., Rodriguez, C., Voorhees, P. M., Weisel, K. C., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01504 · Cited by 134 · see citing works
Cordonnier, C., Cesaro, S., Maschmeyer, G., Einsele, H., Donnelly, J. P., Alanio, A., Hauser, P. M., Lagrou, K., Melchers, W. J. G., Helweg‐Larsen, J., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw155 · Cited by 130 · see citing works
Self-citationSubklewe, M. S. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020001792 · Cited by 125 · see citing works
Harrison, S. J., Minnema, M. C., Lee, H. C., Spencer, A., Kapoor, P., Madduri, D., Larsen, J., Ailawadhi, S., Kaufman, J. L., Raab, M. S., et al. (2020) · Blood · doi:10.1182/blood-2020-134063 · Cited by 112 · see citing works
Clave, E., Agbalika, F., Bajzik, V., de Latour, R. P., Trillard, M., Rabian, C., Scieux, C., Devergié, A., Socié, G., Ribaud, P., et al. (2004) · Transplantation · doi:10.1097/01.tp.0000093997.83754.2b · Cited by 109 · see citing works
Bispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 101 · see citing works
Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody
Xu, H., Cheng, M. H., Guo, H.-F., Chen, Y., Huse, M., & Cheung, N. V. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0230-t · Cited by 92 · see citing works
Nuclear Imaging of Bacterial Infection: The State of the Art and Future Directions
Polvoy, I., Flavell, R. R., Rosenberg, O. S., Ohliger, M. A., & Wilson, D. M. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.244939 · Cited by 87 · see citing works
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
Aleman, A., Upadhyaya, B., Tuballes, K., Kappes, K., Gleason, C., Beach, K. F., Agte, S., Srivastava, K., Andre, D., Azad, A., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.015 · Cited by 73 · see citing works
Therapy and Management of Pneumocystis jirovecii Infection
White, P. L., Price, J. S., & Backx, M. (2018) · Journal of Fungi · doi:10.3390/jof4040127 · Cited by 68 · see citing works
Risk of infections with B-cell maturation antigen-directed immunotherapy in multiple myeloma
Mohan, M., Nagavally, S., Dhakal, B., Radhakrishnan, S. V., Chhabra, S., D’Souza, A., & Hari, P. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006178 · Cited by 66 · see citing works
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Ludwig, H., Sonneveld, P., Facon, T. T. F., Miguel, J. F. S., Avet‐Loiseau, H., Mohty, M., Mateos, M.-V., Moreau, P., Cavo, M., Pawlyn, C., et al. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00278-7 · Cited by 65 · see citing works
Self-citationSearle, E. J., Quach, H., Wong, S. W. K., Costa, L. J., Hulin, C., Janowski, W., Berdeja, J. G., Anguille, S., Matous, J., Touzeau, C., et al. (2022) · Blood · doi:10.1182/blood-2022-159711 · Cited by 61 · see citing works
Madduri, D., Rosko, A. E., Brayer, J. B., Zonder, J. A., Bensinger, W., Li, J., Xu, L., Adriaens, L., Chokshi, D., Zhang, W., et al. (2020) · Blood · doi:10.1182/blood-2020-139192 · Cited by 58 · see citing works
Brioli, A., Klaus, M., Sayer, H. G., Scholl, S., Ernst, T., Hilgendorf, I., Scherag, A., Yomade, O., Schilling, K., Hochhaus, A., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03621-1 · Cited by 56 · see citing works
Bahlis, N. J., Tomasson, M. H., Mohty, M., Niesvizky, R., Nooka, A. K., Manier, S., Maisel, C., Jethava, Y. S., Martínez‐López, J., Prince, H. M., et al. (2022) · Blood · doi:10.1182/blood-2022-162440 · Cited by 55 · see citing works
Self-citationSebag, M., Raje, N. S., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Dube, H., Damore, M. A., et al. (2021) · Blood · doi:10.1182/blood-2021-150519 · Cited by 54 · see citing works
Self-citationKrishnan, A. Y., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez‐Otero, P., Askari, E., Mateos, M., Costa, L. J., Verona, R. I., et al. (2021) · Blood · doi:10.1182/blood-2021-146868 · Cited by 52 · see citing works
Self-citationCMV induces expansion of highly polyfunctional CD4+ T cell subset coexpressing CD57 and CD154
Pera, A., Vasudev, A., Tan, C. T. Y., Kared, H., Solana, R., & Larbi, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.4a0316-112r · Cited by 50 · see citing works
Hammons, L. R., Szabó, A., Janardan, A., Dhakal, B., Chhabra, S., D’Souza, A., & Mohan, M. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.38961 · Cited by 49 · see citing works
Branagan, A. R., Duffy, E. J., Albrecht, R. A., COOPER, D. L., Seropian, S., Parker, T. L., Gan, G., Li, F., Zelterman, D. A., Boddupalli, C. S., et al. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.025 · Cited by 48 · see citing works
Kumar, S. K., D’Souza, A., Shah, N. D., Rodriguez, C., Voorhees, P. M., Bueno, O. F., Buelow, B. D., Freise, K. J., Yue, S., Pothacamury, R. K., et al. (2021) · Blood · doi:10.1182/blood-2021-150757 · Cited by 47 · see citing works
Raje, N., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., et al. (2022) · Blood · doi:10.1182/blood-2022-166494 · Cited by 46 · see citing works
Self-citationT-cell–redirecting bispecific antibodies in multiple myeloma: a revolution?
Moreau, P., & Touzeau, C. (2022) · Blood · doi:10.1182/blood.2021014611 · Cited by 45 · see citing works
Self-citationLeblay, N., Maity, R., Hasan, F., & Neri, P. E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00636 · Cited by 44 · see citing works
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
Caro, J., Braunstein, M. J., Williams, L. S., Bruno, B., Kaminetzky, D., Siegel, A., Razzo, B. M., Alfandari, S., Morgan, G. J., Davies, F. E., et al. (2022) · Leukemia · doi:10.1038/s41375-021-01506-9 · Cited by 39 · see citing works
COOPER, D. L., Madduri, D., Lentzsch, S., Jagannath, S., Li, J., Boyapati, A., Adriaens, L., Chokshi, D., Zhu, M., Lowy, I., et al. (2019) · Blood · doi:10.1182/blood-2019-126818 · Cited by 38 · see citing works
Zonder, J. A., Richter, J. R., Bumma, N., Brayer, J. B., Hoffman, J. E., Bensinger, W., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., et al. (2021) · Blood · doi:10.1182/blood-2021-144921 · Cited by 36 · see citing works
How I treat triple‐class refractory multiple myeloma
Costa, L. J., Hungria, V., Mohty, M., & Mateos, M. (2022) · British Journal of Haematology · doi:10.1111/bjh.18185 · Cited by 29 · see citing works
Self-citationA simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Encinas, C., Hernández‐Rivas, J., Oriol, A., Rosiñol, L., Blanchard, M. J., Bellón, J. M., García‐Sánz, R., de la Rubia, J., de la Guía, A. L., Ubieto, A. J., et al. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00652-2 · Cited by 29 · see citing works
Self-citationLeleu, X. P., Gay, F., Flament, A., Allcott, K., & Delforge, M. (2017) · Annals of Hematology · doi:10.1007/s00277-017-3191-7 · Cited by 28 · see citing works
Self-citationPrevention of infections including vaccination strategies in multiple myeloma
Ludwig, H., & Kumar, S. K. (2022) · American Journal of Hematology · doi:10.1002/ajh.26766 · Cited by 27 · see citing works
Self-citationMinnema, M. C., Krishnan, A. Y., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez‐Otero, P., Morillo, D., Mateos, M., Costa, L. J., Caers, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.8015 · Cited by 27 · see citing works
Self-citationCytomegalovirus reactivation in patients with multiple myeloma
Hasegawa, T., Aisa, Y., Shimazaki, K., Ito, C., & Nakazato, T. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12551 · Cited by 23 · see citing works
Risk and impact of invasive fungal infections in patients with multiple myeloma
Tsai, C., Liu, Y., Kuan, A. S., Lee, K., Yeh, C., Lee, Y.-T., Hsiao, L., Ko, P., Wang, H., Chen, P., et al. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04125-z · Cited by 23 · see citing works
Riley, C. H., Hutchings, M., Yoon, S.-S., Koh, Y., Manier, S., Facon, T. T. F., Harrison, S. J., Er, J., Volzone, F., Pinto, A., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000843612.41180.42 · Cited by 22 · see citing works
Self-citationEfficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma
Lancman, G., Lozada, K. S., Athar, N., Jacobs, S. E., Doucette, J. T., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.12.026 · Cited by 22 · see citing works
Mohyuddin, G. R., Aziz, M., McClune, B. L., Abdallah, A.-O. A., & Qazilbash, M. H. (2019) · European Journal Of Haematology · doi:10.1111/ejh.13374 · Cited by 19 · see citing works
Tay, K. H., Slavin, M. A., Thursky, K., Coussement, J., Worth, L. J., Teh, B. W., Khot, A. S., Tam, C. S. L., & Yong, M. K. (2021) · Internal Medicine Journal · doi:10.1111/imj.15496 · Cited by 17 · see citing works
Rodríguez‐Otero, P., D’Souza, A., Reece, D. E., van de Donk, N. W. C. J., Chari, A., Krishnan, A., Martin, T. G., Mateos, M., Morillo, D., Hurd, D. D., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000843644.02496.66 · Cited by 16 · see citing works
Self-citationDiLillo, D. J., Olson, K., Mohrs, K., Meagher, T. C., Bray, K., Sineshchekova, O., Startz, T., Retter, M. W., Godin, S., Delfino, F. J., et al. (2018) · Blood · doi:10.1182/blood-2018-99-112500 · Cited by 16 · see citing works
Jakubowiak, A. J., Bahlis, N. J., Raje, N. S., Costello, C., Dholaria, B. R., Solh, M. M., Levy, M. Y., Tomasson, M. H., Dube, H., Damore, M. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.8014 · Cited by 16 · see citing works
Self-citationAn Emerging Role of B Cell Immunity in Susceptibility to Pneumocystis Pneumonia
Kolls, J. K. (2017) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0360ed · Cited by 15 · see citing works
van de Donk, N. W. C. J., Bahlis, N. J., Mateos, M., Weisel, K. C., Dholaria, B., Garfall, A. L., Goldschmidt, H., Martin, T. G., Morillo, D., Reece, D. E., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000843624.82943.92 · Cited by 14 · see citing works
Self-citationWei, N., Wang, Y., Wang, J., Wu, L., & Wang, Z. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01193-7 · Cited by 11 · see citing works
Adams, H. J. A., & Kwee, T. C. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03881-x · Cited by 9 · see citing works
Raab, M., Cohen, Y. C., Schjesvold, F. H., Aardalen, K., Oka, A., Spencer, A. G., Wermke, M., Hari, P., Kaufman, J. L., Cafro, A. M., et al. (2022) · HemaSphere · doi:10.1097/01.hs9.0000846616.21003.5d · Cited by 7 · see citing works
New immunotherapeutic target in myeloma
Chng, W. J. (2022) · Blood · doi:10.1182/blood.2022015481 · Cited by 5 · see citing works
Ding, X., Ding, J., Gu, H., & Zhong, C. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-022-06851-8 · Cited by 3 · see citing works
P-113: Infectious toxicities in patients treated with bispecific antibodies in multiple myeloma
Sáez, A., López‐Muñoz, N., Sánchez‐Pina, J. M., Alonso, R., Cuéllar, C., lázaro, P., Ubieto, A. J., Calbacho, M., & López, J. M. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(22)00443-8 · Cited by 2 · see citing works
Vaccination Against SARS-CoV-2 for Myeloma Patients: Do We Need a Booster Dose and How Frequent?
Terpos, E. (2022) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2022.09.1191 · Cited by 1 · see citing works
Flagged first, then by citations
1 of the 72 references couldn’t be matched to a known paper.
Research works printed but not linked: 3
- [7]Pfizer. Pfizer’s elranatamab granted FDA breakthrough therapy designation for relapsed or refractory multiple myeloma. 2022. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-granted-fda-breakthrough-therapy.
- [8]Pfizer. Pfizer’s elranatamab receives FDA and EMA filing acceptance. 2023. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-elranatamab-receives-fda-and-ema-filing-acceptance.
- [49]Voorhees, P. A Phase 1 first-in-human study of ABBV-383, a BCMA x CD3 bispecific T-Cell-redirecting Antibody, As Monotherapy In Patients With Relapsed/refractory Multiple Myeloma. American Society Of Hematology (ASH) Annual Meeting and Exposition, 2022. PMC9622641 36029527
Cited by
Sorted by citations
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664 · see citing works
Self-citationLinvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Bumma, N., Richter, J. R., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01008 · Cited by 191 · see citing works
Dimopoulos, M. A., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M., Zweegman, S., Cook, G., Engelhardt, M. M., Delforge, M., Hájek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 196 · see citing works
Self-citationRodríguez‐Otero, P., Usmani, S. Z., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X. P., Pérez‐Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M., Einsele, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00043-3 · Cited by 157 · see citing works
Self-citationTalquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Cohen, Y. C., Magen, H., Gatt, M. E., Sébag, M., Kım, K., Min, C., Ocio, E. M., Yoon, S.-S., Chu, M. P., Rodríguez‐Otero, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2406536 · Cited by 118 · see citing works
Self-citationReal-world analysis of teclistamab in 123 RRMM patients from Germany
Riedhammer, C., Bassermann, F. C., Besemer, B., Bewarder, M., Brunner, F., Carpinteiro, A., Einsele, H., Faltin, J., Frenking, J. H., Gezer, D., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02154-5 · Cited by 123 · see citing works
Self-citationFrerichs, K. A., Verkleij, C. P. M., Mateos, M., Martin, T. G., Rodriguez, C., Nooka, A. K., Banerjee, A., Chastain, K. M., Perales‐Puchalt, A., Stephenson, T., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011658 · Cited by 105 · see citing works
Self-citationNooka, A. K., Rodriguez, C., Mateos, M., Manier, S., Chastain, K. M., Banerjee, A., Kobos, R., Qi, K., Verona, R. I., Doyle, M., et al. (2023) · Cancer · doi:10.1002/cncr.35107 · Cited by 97 · see citing works
Self-citationTeclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 94 · see citing works
“36– 40 Notably, Tec-Dara was administered per approved daratumumab dosing schedule, with monthly teclistamab dosing from cycle 7 onwards, potentially easing treatment burden and providing a regimen familiar to healthcare providers.”
Self-citationBispecific antibodies in the treatment of multiple myeloma
Devasia, A. J., Chari, A., & Lancman, G. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01139-y · Cited by 94 · see citing works
Costa, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 87 · see citing works
Self-citationJourdes, A., Cellerin, E., Touzeau, C., Harel, S., Denis, B., Escure, G., Faure, E., Jamard, S., Danion, F., Sonntag, C., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.02.023 · Cited by 77 · see citing works
Touzeau, C., Krishnan, A. Y., Moreau, P., Perrot, A., Usmani, S. Z., Manier, S., Cavo, M., Chamorro, C. M., Nooka, A. K., Martin, T. G., et al. (2024) · Blood · doi:10.1182/blood.2023023616 · Cited by 71 · see citing works
Self-citationStepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Qin, X., Ning, W., Liu, H., Liu, X., Luo, W., & Xia, N. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.027 · Cited by 59 · see citing works
Comparison of infectious complications with BCMA-directed therapies in multiple myeloma
Nath, K., Shekarkhand, T., Nemirovsky, D., Derkach, A., Costa, B. A., Nishimura, N., Farzana, T., Rueda, C., Chung, D. J., Landau, H. J., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01043-5 · Cited by 53 · see citing works
Self-citationDual Targeting of Extramedullary Myeloma with Talquetamab and Teclistamab
Kumar, S. K., Mateos, M., Ye, J. C., Atrash, S., Magen, H., Quach, H., Chu, M. P., Trudel, S., Richter, J. R., Rodríguez‐Otero, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2514752 · Cited by 51 · see citing works
Self-citationBispecific antibodies: unleashing a new era in oncology treatment
Shui, L., Wu, D., Yang, K., Sun, C., Li, Q., & Yin, R. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02390-y · Cited by 50 · see citing works
Jaggi, T. K., Agarwal, R., Tiew, P. Y., Shah, A., Lydon, E., Hage, C. A., WATERER, G. W., Langelier, C., Delhaès, L., & Chotirmall, S. H. (2024) · European Respiratory Journal · doi:10.1183/13993003.00803-2024 · Cited by 50 · see citing works
Tan, C. R. C., Asoori, S., Huang, C., Brunaldi, L. A. M., Popat, R., Kastritis, E., Martínez‐López, J., Bansal, R., Corraes, A. D. M. S., Chhabra, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01259-z · Cited by 43 · see citing works
Mohan, M., Szabó, A., Cheruvalath, H., Clennon, A., Bhatlapenumarthi, V., Patwari, A., Balev, M., Bhutani, D., Shrestha, A., Thanendrarajan, S., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01282-0 · Cited by 42 · see citing works
Banerjee, R. K., Mohan, M., Rejeski, K., Puliafito, B. R., Cirstea, D. D., Kaur, G., Midha, S., McCaughan, G. J. B., Kumar, N. M., Mehra, N., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016490 · Cited by 40 · see citing works
Self-citationNeri, P., Leblay, N., Lee, H., Gullà, A., Bahlis, N. J., & Anderson, K. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00913-y · Cited by 37 · see citing works
Self-citationMa, H., Yan, Q., Ma, J., Li, D.-F., & Yang, J.-L. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i10.1295 · Cited by 31 · see citing works
Pan, D., & Richter, J. R. (2024) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-024-00740-z · Cited by 27 · see citing works
Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Braun, A., Gouni, S., Pulles, A. E., Strati, P., Minnema, M. C., & Budde, L. E. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_433516 · Cited by 26 · see citing works
Perrot, A., Hulin, C., Boumendil, A., Manjra, H., Leveque, A., Croizier, C., Dony, A., Mohty, M., Roussel, M., Manier, S., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.286118 · Cited by 25 · see citing works
Self-citationArvanitis, P., Tziotis, A., Papadimatos, S., & Farmakiotis, D. (2025) · Current Oncology · doi:10.3390/curroncol32040198 · Cited by 22 · see citing works
Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Mohan, M., Oekelen, O. V., Akhtar, O. S., Cohen, A. D., & Parekh, S. S. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432204 · Cited by 27 · see citing works
Hadidi, S. A., Heslop, H. E., Brenner, M. K., & Suzuki, M. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.05.039 · Cited by 28 · see citing works
BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them
Rees, M., & Kumar, S. K. (2023) · Leukemia and Lymphoma · doi:10.1080/10428194.2023.2284088 · Cited by 19 · see citing works
Lee, K., Paek, H., Huang, L., Hilton, C. B., Datta, S., Higashi, J., Ofoegbu, N., Wang, J., Rubinstein, S. M., Cowan, A. J., et al. (2024) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2024.101589 · Cited by 23 · see citing works
Tix, T., Alhomoud, M., Shouval, R., Iacoboni, G., Cliff, E. R. S., Hansen, D. K., Usmani, S. Z., Salles, G. A., Perales, M., dos Santos, D. M. C., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.048 · Cited by 22 · see citing works
Jelinek, T., Žihala, D., Zabaleta, A., Kostopoulos, I. V., Souček, O., Venglár, O., Moreno, C., Fotiou, D., Radova, E., Tamariz‐Amador, L., et al. (2025) · Blood · doi:10.1182/blood.2025029572 · Cited by 20 · see citing works
Parrondo, R. D., Ailawadhi, S., & Cerchione, C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394048 · Cited by 21 · see citing works
Sassine, J., Siegrist, E. A., & Chemaly, R. F. (2025) · Viruses · doi:10.3390/v17010133 · Cited by 19 · see citing works
Wang, X., Zhao, A., Zhu, J., & Niu, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1348955 · Cited by 14 · see citing works
Richardson, T., Schütte, D., Kobbe, G., Baermann, B., Holderried, T. A. W., Schmitz, F., Crysandt, M. M., Hallek, M. J., Scheid, C., Holtick, U., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015008 · Cited by 16 · see citing works
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
Garfall, A. L., Banerjee, R. K., Frenzel, L., Khandanpour, C., Lin, Y., Ottoni, E. L., Rifkin, R. M., Rockwell, S., Rodriguez, C., Villefort, H., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1630146 · Cited by 16 · see citing works
Golmohammadi, M., Raza, S., Albayyadhi, M., Sholehrasa, H., Khouri, J., Williams, L., Hansen, D. K., Moradi, A., Xu, X., Albliwi, M., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01334-5 · Cited by 18 · see citing works
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
Yee, A. J. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01091-x · Cited by 17 · see citing works
Bispecific antibody targets and therapies in multiple myeloma
Rees, M. J., Abdallah, N. H., Yohannan, B., & Gonsalves, W. I. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1424925 · Cited by 14 · see citing works
Techaapornkun, P., Rojpalakorn, W., Mejun, N., Khaniya, A., Thammahong, A., Thu, M. S., Hirankarn, N., & Pitakkitnukun, P. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06524-6 · Cited by 14 · see citing works
Arvanitis, P., Farmakiotis, D., & Pelcovits, A. (2024) · Current Oncology · doi:10.3390/curroncol31050202 · Cited by 13 · see citing works
Wattana, M. K., Rowland, J., Qdaisat, A. Z., Levavi, H., Anagnostou, T., Sanchez, L. J., Friedlander, P. A., Rohs, N. C., Lipe, D. N., & Richter, J. R. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102889 · Cited by 14 · see citing works
Cai, Z., Xia, Z., He, A., Dong, Y., Wang, Y., Liao, A., Song, Y., Song, J., Uhlar, C., Chastain, K. M., et al. (2024) · Cancer · doi:10.1002/cncr.35665 · Cited by 12 · see citing works
CAR T-cell therapy and bispecific antibodies in the management of multiple myeloma
Dima, D., Banerjee, R., & Hansen, D. K. (2025) · Hematology · doi:10.1182/hematology.2025000721 · Cited by 11 · see citing works
Alshammari, F., Alrajhi, A. M., & Howaidi, J. (2025) · Hematology · doi:10.1080/16078454.2024.2448898 · Cited by 11 · see citing works
Rafei, H., & Rezvani, K. (2024) · British Journal of Haematology · doi:10.1111/bjh.19668 · Cited by 10 · see citing works
Liu, Z., Petinrin, O. O., Chen, N., Toseef, M., Liu, F., Zhu, Z., Qi, F., & Wong, K. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-10000-3 · Cited by 10 · see citing works
Use of Immunoglobulin Replacement Therapy in Clinical Practice: A Review
Ahmed, J., Choi, Y., Ko, T., Lim, J. T., & Hajjar, J. (2024) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-24-7 · Cited by 10 · see citing works
Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma
Riedhammer, C., Düll, J., Kestler, C., Kadel, S., Franz, J., Weis, P., Eisele, F., Zhou, X., Steinhardt, M., Scheller, L., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05586-8 · Cited by 10 · see citing works
Self-citationDerman, B. A., Tan, C. R. C., Steinfield, I., Wilson, F. R., Lin, D., Wu, B., Fernandez, M., Fowler, J., Paner-Straseviciute, A., Kim, N., et al. (2025) · Cancers · doi:10.3390/cancers17071235 · Cited by 9 · see citing works
Guo, Y., Niu, J., Cardé, N. A. Q., Wu, L. S., Miao, X., Hanson, S., Su, Y., Pérez‐Ruixo, C., Vishwamitra, D., Chastain, K. M., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01149-1 · Cited by 9 · see citing works
Integrating Immune Therapies for the Treatment of Multiple Myeloma
Mikkilineni, L., & Sidana, S. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7100 · Cited by 9 · see citing works
Catamero, D., Ray, C., Purcell, K., Leahey, S., Esler, E., Rogers, S., Hefner, K., O’Rourke, L., Gray, K. S., Tolbert, J. A., et al. (2024) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2024.151712 · Cited by 9 · see citing works
Li, W., Zhao, D., Yu, J., Dong, W., Wang, Z., & Yan, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1565407 · Cited by 8 · see citing works
Mancuso, K., Talarico, M., Manzato, E., Barbato, S., Tacchetti, P., Zamagni, E., & Cavo, M. (2025) · Cancers · doi:10.3390/cancers17091514 · Cited by 7 · see citing works
Piron, B., Rodrigo, L., Tessoulin, B., Gastinne, T., Dubruille, V., Letailleur, V., Antier, C., Lok, A., Leroy, E., Moreau, P., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.10.024 · Cited by 7 · see citing works
Self-citationInfections after bispecific antibodies in B-cell lymphomas
Kim, D. H., Lee, N., Koh, Y., Jo, H. J., Kang, C. K., Choe, P. G., Park, W. B., Lee, C. M., Byun, J. M., & Kim, N. J. (2026) · Blood Advances · doi:10.1182/bloodadvances.2025017366 · Cited by 7 · see citing works
Sandherr, M., Schalk, E., Heinz, W., Köhler, P., Krause, S. W., Liss, B., Kausche, L., Link, H., Mellinghoff, S. C., Schmidt-Hieber, M., et al. (2026) · European Journal of Cancer · doi:10.1016/j.ejca.2026.116244 · Cited by 7 · see citing works
FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial
Cohen, A. D., Richter, J. R., Trudel, S., Lesokhin, A. M., Laubach, J. P., Thomas, S. K., Harrison, S. J., Costa, L. J., Spencer, A. G., Fonseca, R., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04522-3 · Cited by 7 · see citing works
Self-citationNovellis, D. D., Fontana, R., Serio, B., Vaccaro, E., Guariglia, R., Morini, D., Rizzo, M., Giudice, V., & Selleri, C. (2024) · Cancer Medicine · doi:10.1002/cam4.7402 · Cited by 7 · see citing works
The impact of institutional measures on optimal use of intravenous immunoglobulin
Champagne, J., Desîlets, A., Roy, G., Landon‐Cardinal, O., Chapdelaine, H., Matte, G., Bouchard, C., Rioux‐Massé, B., & Lemay, A. (2024) · Transfusion · doi:10.1111/trf.18031 · Cited by 7 · see citing works
Supportive care in myeloma—when treating the clone alone is not enough
Zweegman, S., & van de Donk, N. W. C. J. (2024) · Hematology · doi:10.1182/hematology.2024000579 · Cited by 7 · see citing works
Derman, B. A., Roach, M., Lin, D., Wu, B., Murphy, R., Kim, N., Doyle, M., Prood, N., Fowler, J., Marshall, A., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2352856 · Cited by 6 · see citing works
Pei, C., Boghdadly, Z. E., Blackburn, L. M., Sharma, N., Bumma, N., Khan, A., Devarakonda, S. S., Umyarova, E. R., Benson, D., Rosko, A. E., et al. (2025) · Blood Neoplasia · doi:10.1016/j.bneo.2025.100097 · Cited by 6 · see citing works
Approaches To Managing Relapsed Myeloma: Switching Drug Class or Retreatment With Same Drug Class?
Vijjhalwar, R., Kannan, A., Fuentes-Lacouture, M. C., & Ramasamy, K. (2025) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-025-02008-9 · Cited by 6 · see citing works
Self-citationOgiya, D., Suzuki, R., Goto, S., Nakagawa, Y., Nasukawa, M., Iwata, S., Kawai, H., Toyosaki, M., Machida, S., Onizuka, M., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06689-0 · Cited by 6 · see citing works
Wang, M., Wang, C., Deng, J., Wang, H., Sun, C., Luo, S., & Hu, Y. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2906216 · Cited by 9 · see citing works
Park, T., Jang, S., Koh, Y., Shin, D., Yoon, S., Lee, C. M., Jo, H. J., Choe, P. G., Park, W. B., Kim, N. J., et al. (2025) · Journal of Korean Medical Science · doi:10.3346/jkms.2025.40.e86 · Cited by 6 · see citing works
Dean, E. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1705345 · Cited by 5 · see citing works
Supportive care measures for bispecific T-cell engager therapies in haematological malignancies
Chen, L., & Kothari, J. (2024) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000699 · Cited by 5 · see citing works
Multiple myeloma and infections in the era of novel treatment modalities
Akhmedov, M., Zeynalova, P. A., & Феденко, А. А. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107544 · Cited by 5 · see citing works
Defining infection risk of bispecific antibodies for myeloma
Hammond, S. P. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024013813 · Cited by 5 · see citing works
Self-citationPatient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency
Cowan, J., Na, I., Gladiator, A., Kamieniak, M. M., & Mustafa, S. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1528414 · Cited by 5 · see citing works
T-cell engaging antibodies for B-cell lymphomas
Kim, D. H., & Kim, T. M. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.12.002 · Cited by 5 · see citing works
Understanding Infection Risk with Anti-BCMA Bispecific Antibodies
Garfall, A. L., & Stadtmauer, E. A. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0157 · Cited by 5 · see citing works
Current status of bispecific antibodies and CAR-T therapies in multiple myeloma
Szlasa, W., & Dybko, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112043 · Cited by 5 · see citing works
Advancements in bispecific antibodies for multiple myeloma: What's new and what lies ahead
Mouhieddine, T. H., Costa, B. A., & Richter, J. R. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.12.001 · Cited by 6 · see citing works
Akiyama, H., Kakiuchi, S., Sakamoto, A., Tomigaki, N., Fujioka, S., Harima, I., Niwa, R., Takagi, I., Kozuki, Y., Miyata, Y., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2025.1705843 · Cited by 4 · see citing works
Progressive Multifocal Leukoencephalopathy (PML) in 2 Patients Treated With Elranatamab
Tomkins, O. M., Maamari, R. G., Douthwaite, S. T., Roy, A., Bain, H., Kohli, N., de Lavallade, H., Kazmi, M. A., Sachchithanantham, S., Dmello, T., et al. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2026.01.017 · Cited by 4 · see citing works
Little, J. S., Pena, A. M., Kim, E. B., Yee, A. J., Nadeem, O., Midha, S., Sperling, A. S., Munshi, N. C., Raje, N. S., Frigault, M. J., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016748 · Cited by 4 · see citing works
Self-citationNishimura, N., Nakashima, H., Yoshikuni, K., Numata, A., & Ogawa, R. (2025) · Journal of Pharmaceutical Health Care and Sciences · doi:10.1186/s40780-025-00506-6 · Cited by 4 · see citing works
Rodríguez‐Otero, P., Moreau, P., Mateos, M., Krauth, M. T., Rasche, L., Kastritis, E., Oriol, A., Zamagni, E., Albrecht, C., Rubio‐Azpeitia, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.003 · Cited by 4 · see citing works
Self-citationPaulsen, J. S., & Slørdahl, T. S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1722579 · Cited by 4 · see citing works
Segers, F., & Delforge, M. (2026) · Targeted Oncology · doi:10.1007/s11523-025-01189-7 · Cited by 4 · see citing works
Towards personalized and rational use of immunoglobulins amid expanding indications and shortages
Goubran, H. A., Ragab, G., Seghatchian, J., & Burnouf, T. P. R. (2024) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2024.103987 · Cited by 4 · see citing works
Davis, J. A., McGann, M., Marini, J., & Hashmi, H. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2344650 · Cited by 4 · see citing works
Encinas, C., Blanchard, M. J., Alonso, R., Hernández‐Rivas, J., Tamayo, R. R., Machado-Vílchez, M., Martínez‐López, J., & Mateos, M. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.06.012 · Cited by 5 · see citing works
Self-citationDye, B., Gromer, D. J., Bibi, M., Siegrist, E. A., & Sassine, J. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.007 · Cited by 3 · see citing works
Reshaping multiple myeloma treatment: recent breakthroughs
Martino, E. A., Caserta, S., Vigna, E., Bruzzese, A., Mendicino, F., Alvaro, M. E., Labanca, C., Lucia, E., Olivito, V., Amodio, N., et al. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2610373 · Cited by 3 · see citing works
Siffel, C., Davids, M. S., Anderson‐Smits, C., Kamieniak, M. M., Ren, K., Ardeshir‐Rouhani‐Fard, S., Drishti, S., & Richter, J. R. (2025) · Advances in Hematology · doi:10.1155/ah/5340241 · Cited by 3 · see citing works
Bispecific Antibody Therapy for Multiple Myeloma: A Practical Toolkit
Rodriguez, C., Touzeau, C., Crusoé, E. D. Q., Pericole, F. V., & Hungria, V. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.12.015 · Cited by 3 · see citing works
Consensus guidelines for antibacterial prophylaxis in patients with neutropenia
Lindsay, J., Yeoh, D. K., Teh, B. W., Reynolds, G. K., Henden, A. S., McQuilten, Z., Wheeler, M., Hamilton, A., Nelson, A. C., Nakagaki, M., et al. (2025) · Internal Medicine Journal · doi:10.1111/imj.70250 · Cited by 3 · see citing works
Giesen, N., Mellinghoff, S. C., Khatamzas, E., Korell, F., Hentrich, M., Einsele, H., Henze, L., Heußel, C., Hohmann, C., Jensen, B.-E. O., et al. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06769-9 · Cited by 3 · see citing works
Self-citationDerman, B. A., Liu, J. J., Bouchard, N., Figg, L., LaPorte, J., Goorha, S., Pagan, K. A., Tandra, A., Varshavsky, A., Ko, G., et al. (2026) · Current Medical Research and Opinion · doi:10.1080/03007995.2026.2626367 · Cited by 3 · see citing works
Lasagna, A., Re, M. D., Danesi, R., Andreoni, M., Tessitore, D., Maïo, M. D., Silvestris, N., & Pedrazzoli, P. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105253 · Cited by 4 · see citing works
Lee, H. C., Plattel, W. J., Harrison, S. J., Sborov, D. W., Lentzsch, S., Spencer, A. G., Niesvizky, R., Trudel, S., Mollee, P. N., Vij, R., et al. (2026) · Blood · doi:10.1182/blood.2025032044 · Cited by 3 · see citing works
Rejeski, K., Banerjee, R. K., & Hill, J. A. (2026) · Blood · doi:10.1182/blood.2025032298 · Cited by 3 · see citing works
Howard, A. J., Concepcion, I., Wang, A. X., Hamadeh, I. S., Hultcrantz, M. L., Mailankody, S., Tan, C. R. C., Korde, N., Lesokhin, A. M., Hassoun, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024012871 · Cited by 3 · see citing works
Self-citation
- Authors
- Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., Patel, K., Ramasamy, K., & Mateos, M.-V.
- Affiliations
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Universitätsklinikum Würzburg (DE)
- OhioHealth (US)
- Azienda Ospedaliera Citta' della Salute e della Scienza di Torino (IT)
- Massachusetts General Hospital (US)
- Memorial Sloan Kettering Cancer Center (US)
- Emory University (US)
- Wilhelminen Hospital (AT)
- Centre Hospitalier Universitaire de Nantes (FR)
- The University of Texas MD Anderson Cancer Center (US)
- University of Oxford (GB)
- Corresponding author
- Raje, Noopur
- ORCID
- Venue
- Blood Cancer Journal
- Published
- 2023-08-01
- Volume
- 13
- Issue
- 1
- Pages
- 116-116
- ISSN
- 2044-5385 (ISSN-L)
- PMC
- PMC10394080
- OpenAlex
- W4385456897
- Cited by
- 209
- References
- 72
- Citations by year
- 2026: 81 · 2025: 64 · 2024: 54 · 2023: 10
- FWCI
- 43.17
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Blood Cancer Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Monoclonal and Polyclonal Antibodies Research
- Keywords
- multiple myeloma, bispecific antibodies, infection risk, infection control, infection treatment, hypogammaglobulinemia, neutropenia, COVID-19 pandemic, HBV reactivation, intravenous immunoglobulin, colony-stimulating factors, Pneumocystis carinii pneumonia prophylaxis, antifungal prophylaxis, viral and bacterial infections
- MeSH terms
- COVID-19, Agammaglobulinemia, Humans, Multiple Myeloma, Neutropenia, Antibodies, Bispecific, Neurotoxicity Syndromes, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
